Background {#Sec1}
==========

Chronic obstructive pulmonary disease (COPD) is a persistent, irreversible, progressive disease exacting a heavy toll on patients and caregivers and is a leading cause of morbidity and mortality worldwide \[[@CR1]--[@CR4]\]. Estimates indicate that more than 10 % of the adult population are affected by COPD, and one in four adults over the age of 35 will develop COPD in their lifetime \[[@CR5], [@CR6]\]. In Canada, COPD is project to be the fourth leading cause of death behind heart disease, cancer and stroke and is expected to be the third leading cause of death by 2020 \[[@CR3]\]. Exposure to environmental factors is thought to be the major underlying cause of COPD, with smoking being the most important risk factor \[[@CR7]--[@CR9]\]. Comorbidities, such as cardiovascular disease, are very common and are thought to contribute to the vast majority of COPD deaths \[[@CR10]--[@CR12]\].

The unique features of the Canadian universal healthcare system provide different challenges for government and health care providers alike in the delivery and implementation of health services. With the substantial burden and societal importance of COPD, it is important for Canadian healthcare professionals and decision makers to remain up to date with evidence of managing and treating COPD. A sizeable body of research on the burden of COPD in Canada has been conducted in recent years; however, a systematic review of recent evidence is lacking. The overall purpose of this systematic review is to update the knowledge of the burden of COPD in Canada by summarizing the most current, evidence-based information. The specific objective is to summarize the recent literature describing the clinical, humanistic and economic burden of COPD among Canadians.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

We conducted a search of the PubMed, EMBASE, and Cochrane databases to identify original research (observational and interventional studies, burden of illness studies, and cost of illness studies) published January 2000 through December 2012 on the burden of COPD in Canada. Non-systematic review articles, letters, editorials, commentaries, studies reporting summaries of meeting proceedings or conferences, abstracts or posters presented at scientific meetings, and studies examining the efficacy or effectiveness of specific pharmacotherapy interventions were not included. Each search was conducted using controlled vocabulary and key words and was limited to articles published in English, studies conducted with Canadian data, and studies involving humans. Additional articles were identified and added to each review through a review of the bibliographies of included articles and if identified in the other literature search (i.e. article with economic data found in humanistic literature search).

Study selection {#Sec4}
---------------

Titles and abstracts of articles identified were carefully screened in the initial review for relevance to the topic by a single reviewer. Articles were selected for inclusion based on predefined acceptance criteria, which included relevant patient population (i.e., adults/children diagnosed with COPD), study design \[randomized controlled trial (RCT), observational study, systematic review/meta-analyses\] and outcome measures (healthcare resource utilization, quality of life, healthcare costs). Complete articles were obtained for any article that categorized as 'included' or 'unsure' after the title and abstract review. All 'unsure' articles were then reviewed to make a final determination of inclusion or exclusion. A second, independent reviewer performed a check on a random sample of 20 % of the articles with discrepancies resolved through consensus. Articles identified as potentially relevant were obtained in full text for further evaluation.

Data abstraction {#Sec5}
----------------

Data abstraction forms were designed a priori. For articles that met predefined inclusion/exclusion criteria, key outcomes were abstracted and tabulated in summary tables. Key outcomes extracted included: emergency department visits, hospitalization and office visits in the clinical burden literature; quality of life measures in the humanistic burden literature; patient and population costs in the economic burden literature. In the economic burden section, reported costs were inflated to 2012 Canadian dollars using the Consumer Price Index from Statistics Canada (<http://www.statcan.gc.ca>). A second, independent reviewer performed a check on a random sample of the data abstracted from 20 % of the articles.

Quality assessment {#Sec6}
------------------

Quality was assessed by using internationally recognized methodological checklists from the National Institute for Health and Care Excellence (NICE) Guidelines Manual for RCT \[[@CR13]\], the strengthening the reporting of observational studies in epidemiology (STROBE) statement \[[@CR14]\] for observational studies, and the PRISMA checklist for systematic reviews and meta-analyses \[[@CR15]\]. The NICE RCT checklist provides an assessment of potential bias in 4 categories: selection, performance, attrition and detection. The STROBE checklist contains 22 items that assess completeness of reporting in observational studies and the 27-item PRISMA checklist provides a similar assessment for systematic reviews and meta-analyses. The information collected in these checklists enabled a decision to be made about the eligibility of the studies for inclusion in this project. A second, independent reviewer performed a quality review check on a random sample of 20 % of the articles.

Results {#Sec7}
=======

Literature search {#Sec8}
-----------------

A total of 495 studies were identified by the clinical and economic burden literature searches with 58 studies being suitable for inclusion (Fig. [1](#Fig1){ref-type="fig"}). The 58 studies included: 3 systematic review/meta-analyses, 5 RCTs, and 27 cohort, 18 cross-sectional, and 5 case--control studies. A total of 477 studies were identified by the humanistic burden literature searches of which 12 studies were ultimately included (Fig. [2](#Fig2){ref-type="fig"}). The study designs of the 12 included articles were 6 RCTs, 4 cross-sectional and 2 case--control studies.Fig. 1Clinical/economic burden literature search resultsFig. 2Humanistic literature search results

Quality assessment {#Sec9}
------------------

The clinical and economic burden literature included 3 systematic review/meta-analyses which met most of the PRISMA checklist criteria \[[@CR16]--[@CR18]\]. The criteria that were not met included: no description of methods for combining studies (100 %), not addressing risk of bias across studies (67 %) or individual studies (33 %) and not describing study limitations (67 %). Of the 5 RCTs appraised using the NICE RCT methodology checklist, most were rated as having a low risk of bias; however, a high risk of attrition bias was noted for three studies \[[@CR19]--[@CR21]\]. Lastly, the 50 remaining studies were assessed using the STROBE checklist. Many of the cohort studies did not indicate the study design (36 %), lacked reporting sensitivity or sub-group analyses (71 %), and missing or follow-up data was infrequently addressed (68 and 39 % respectively). The methodological limitations identified for the cross-sectional and case--control studies were very similar.

The humanistic burden literature included a total of 6 RCTs which were appraised by the NICE RCT methodology, all of which had an overall low risk of bias. The remaining 6 studies met most of the STROBE criteria; however, only 2 of the 6 studies adequately described the study setting \[[@CR22], [@CR23]\], 2 studies discussed efforts to address sources of bias \[[@CR22], [@CR24]\], and there was an overall lack of reporting on how missing data was addressed as well as sub-group and sensitivity analysis \[[@CR23]--[@CR27]\].

Clinical burden evidence results {#Sec10}
--------------------------------

### Overview {#Sec11}

Of the 57 articles with clinical burden data (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}), the primary data source for 60 % of the studies (retrospective cohort and cross-sectional designs) was the provincial healthcare databases containing hospital records and pharmaceutical claims. The time frame of the included studies varied based on the study design. In general, the prospective designed studies included a much shorter time frame than systematic reviews or retrospective database analyses which often spanned decades.Table 1Summary of emergency department visit evidenceReferencesGeographic region (study years)PatientsArms or cohortsPatients with ED visits, \# (%)\# of ED visitsMean annual ED \# visits/patientPolisena et al. \[[@CR17]\]Calgary (1998--2009)≥60 years (mean age)Telephone support40.6 % of patients0.1 visitsUsual care63.15 % of patients0.4 visitsLabrecque et al. \[[@CR29]\]Montreal (2004)40--75 years, stable COPDSelf-management education (n = 57)Pre-index 1.1 visits\
Post-index 0.2 visitsUsual care (n = 45)Pre-index 0.4 visits\
Post-index 0.4 visitsChapman et al. \[[@CR1]\], Wouters et al. \[[@CR37]\]Canada (1 year study)Diagnosed/undiagnosed COPD patientsAll patients (n = 401)70 patients (17.5 %)151 visits0.38 visitsMoullec et al. \[[@CR28]\]Montreal (2004--2006)Montreal hospital patientsIntegrated care (n = 96)Prior year 27 (28.1 %), Post-Index 28 (29.2 %)Pre and Post-Index 0.5 visitsUsual care (n = 93)Prior year 27 (29.0 %), Post-Index 26 (28.0 %)Pre and Post-Index 0.5 visitsBischoff et al. \[[@CR39]\]COPD patients, ≥40 yearsAll patients (n = 119)Preceding year 0.65 visitsRowe et al. \[[@CR34]\]US, Canada≥55 year, stable COPDCanadian patients (n = 63)Previous year 1.0 visitsTsai et al. \[[@CR45]\]US, Canada≥55 year, stable COPDUnderweight (BMI \<18.5, n = 50)Previous year 2.0 visitsNormal weight (BMI 18.5--24.9, n = 148)Previous year 1.0 visitsOverweight (BMI 25--29.9, n = 105)Previous year 1.0 visitsObese (BMI ≥ 30, n = 92)Previous year 1.0 visitsSin et al. \[[@CR38]\](1992--1997)age ≥65 years, discharged diagnosis of COPDNo inhaled corticosteroid (n = 11,139)Preceding year 1.2 visitsInhaled corticosteroid (n = 11,481)Preceding year 1.6 visitsJohnston et al. \[[@CR32]\]Hamilton, Ontario (Dec 2006--Jan 2007)≥40 year, COPD of mixed severityGOLD stratum 0 (n = 39)Previous year 1.6 visitsGOLD stratum 1 and 2 (n = 31)Previous year 1.4 visitsGOLD stratum 3 and 4 (n = 44)Previous year 1.8 visitsWang et al. \[[@CR35]\]Montreal (2 year study)≥40 years, Moderate-severe COPD hospitalizedAll Patients (n = 282)54 patients (19.1 %)99 visits1.82 visitsRowe et al. \[[@CR30]\], Rosychuk et al. \[[@CR31]\]Alberta (1999--2005)≥55 yearsAll patients (38,638)38,638 patients85,330 visits2.2 visitsGolmohammadi et al. \[[@CR36]\]Edmonton (2000--2002)\>45 yearsRehab program: DSS-S1 (n = 31)Pre 42.1 visits/100 pt-years\
Post 13.6 visits/100 pt-yearsRehab program: DSS-S2A (n = 78)Pre 57.0 visits/100 pt-years\
Post 44.8 visits/100 pt-yearsRehab program: DSS-S2B (n = 51)Pre 29.5 visits/100 pt-years\
Post 16.3 visits/100 pt-yearsRehab program: DSS-S3 (n = 41)Pre 41.0 visits/100 pt-years\
Post 54.4 visits/100 pt-yearsStephenson et al. \[[@CR40]\]Ontario (2003--2010)\>66 years, Concomitant dementia and COPDChEI users (n = 7166)Baseline 538 (7.5 %)ChEI non-users (n = 7166)Baseline 517 (7.2 %)Blais et al. \[[@CR41]\]Quebec (Feb 2003--Jan 2007)≥40 yearsBudesonide/formoterol (n = 1131)10.3 % of patients182 visitsPropionate/salmeterol (n = 1131)13.1 % of patients256 visitsGershon et al. \[[@CR42]\]Ontario (2003--2007)≥66 yearsLong-acting anticholinergic (n = 28,563)12.2 % of patientsLong-acting beta-agonist (n = 17,840)11.7 % of patientsFitzGerald et al. \[[@CR43]\]Canada (1 year study)≥40 yearAll patients (n = 609), all exacerbation (n = 691)193 visitsPatients with exacerbations (n = 278)111 patients (39.9 %)Sedeno et al. \[[@CR21]\]COPD patientsUsual care (n = 81)54.4 % patientsSelf-management group (n = 85)29.9 % patientsBourbeau et al. \[[@CR44]\]Advanced COPD, ≥1 hospitalization for exacerbation in last yearUsual care (n = 95)63.2 % patientsSelf-management care (n = 96)40.6 % patientsMittmann et al. \[[@CR3]\]CanadaModerate and severe COPD exacerbationsAll patients (n = 609), all exacerbation (790 exacerbations)245 visitsModerate exacerbation (639 exacerbations)105 visitsSevere exacerbation (151 exacerbations)140 visitsBeauchesne et al. \[[@CR77]\](1995--2004)COPD patientsHome management program (n = 152)29 visitsDormuth et al. \[[@CR60]\]British Columbia≥45 years, 2.5-year period after public coveragePredicted use6658 visitsObserved use7434 visitsTable 2Summary of hospitalization evidenceReferencesGeographic region (study years)PatientsArms or cohortsHospitalization, \# or  % patients\# of hospital visitsMean annual hospital \# visits/patientTsai et al. \[[@CR45]\]US, Canada≥55 year, stable COPDUnderweight (BMI \<18.5, n = 50)Prior year 0 visitsNormal weight (BMI 18.5--24.9, n = 148)Prior year 0 visitsOverweight (BMI 25--29.9, n = 105)Prior year 0 visitsObese (BMI ≥ 30, n = 92)Prior year 0 visitsRowe et al. \[[@CR34]\]US, Canada≥55 year, stable COPDCanadian patients (n = 63)Prior year 0 visitsJohnston et al. \[[@CR32]\]Hamilton, Ontario (Dec 2006--Jan 2007)≥40 year, COPD of mixed severityGOLD stratum 0 (n = 39)1Prior year 1.3 visitsGOLD stratum 1 and 2 (n = 31)3Prior year 1.2 visitsGOLD stratum 3 and 4 (n = 44)7Prior year 1.5 visitsLabrecque et al. \[[@CR29]\]Montreal (2004)40--75 years, stable COPDSelf-management (n = 57)Prior year 0.7 visits\
Post index 0.3 visitsUsual care (n = 45)Prior year 0.5 visits\
Post index 0.5 visitsMoullec et al. \[[@CR28]\]Montreal (2004--2006)Montreal hospital patientsIntegrated care (n = 96)Prior year 96\
Post-index 38Prior year 1.3 visits\
Post index 0.7 visitsUsual care (n = 93)Prior year 69\
Post-index 55Prior year 1.5 visits\
Post-index 1.3 visitsOhinmaa et al. \[[@CR46]\]AlbertaAdult from Canadian Community Health Survey20--44 years0 visits45--64 years3.45 visits\>65 years5.19 visitsBlais et al. \[[@CR41]\]Quebec (Feb 2003--Jan 2007)≥40 yearsBudesonide/formoterol (n = 1131)8.6 %1300.11 visitsPropionate/salmeterol (n = 1131)12.4 %2330.21 visitsFitzGerald et al. \[[@CR43]\]Canada (1 year study)≥40 year,All patients (n = 609)751120.2 visitsPatients with exacerbations (n = 278)751.5 visitsChapman et al. \[[@CR1]\], Wouters et al. \[[@CR37]\]Canada (1 year study)Diagnosed/undiagnosed COPD patientsAll patients (n = 401)Prior year 14 %0.32 visits (0 visits/year 1999--2005)Wong et al. \[[@CR47]\]Vancouver, British Columbia (winter 2006--2007)Admitted St. Paul's Hospital with AECOPD diagnosisEntire population (n = 109)3.3 visits (6-month readmission rate)Beaulieu et al. \[[@CR48]\]Moderate-severe COPDSelf-administered prescription (n = 46)0.3 visits (prior 6-months)Control (n = 43)0.5 visits (prior 6-months)Sin et al. \[[@CR38]\](1992--1997)age ≥65 years, discharged diagnosis of COPDAll Patients (n = 22,620)5654 (25 % repeat hospitalization)Chen et al. \[[@CR50]\](First admission 1999--2000)COPD In-patients, ≥40 yearsEntire population (n = 108,726)49.1 % rehospitalizationHuiart et al. \[[@CR51]\](1990--1997, 1st COPD treatment)≥55 years, first treatment of COPDAll (n = 5648)10272326101.4 visits/1000 PYFemale (n = 2606)39981274.3 visits/1000 PYMale (n = 3042)6731514126.1 visits/1000 PYSedeno et al. \[[@CR21]\]COPD patientsUsual care (n = 81)36.3 %Self-management group (n = 85)17.2 %Chen et al. \[[@CR76]\]General population, broad (B) and narrow (N) defined cases for COPD hospitalizationAll (n = 6,099,756)B = 257,604, N = 85,189B = 42.2, N = 14.0/1000 PYAge 55--59 (n = 1,332,254)B = 16,671, N = 5129B = 12.5, N = 3.8/1000 PYAge 60--64 (n = 1,207,873)B = 26,904, N = 8579B = 22.3, N = 7.1/1000 PYAge 65--69 (n = 1,121,508)B = 40,823, N = 13,404B = 36.4, N = 12.0/1000 PYAge 70--74 (n = 963,007)B = 51,782, N = 17,310B = 53.8, N = 18.0/1000 PYAge 75--79 (n = 683,520)B = 49,788, N = 16,983B = 72.8, N = 24.8/1000 PYAge 80--84 (n = 450,458)B = 40,666, N = 13,844B = 90.3, N = 30.7/1000 PYAge 85--89 (n = 227,533)B = 21,676, N = 7,046B = 95.3, N = 31.0/1000 PYAge 90+ (n = 113,603)B = 9294, N = 2894B = 81.8, N = 25.5/1000 PYTu et al. \[[@CR78]\]Active smoking adults, ≥15 years of age167 visits (predicted, linear regression)Curkendall et al. \[[@CR79]\](1997--2000)≥40 years, COPD diagnosed with ≥2 bronchodilators within 6-monthsCOPD (n = 11,493)598.36/1000 PY\
CV related; 109.5/1000 PYControls (n = 22,986)221.23/1000 PY\
CV related; 44.66/1,000 PYMittmann et al. \[[@CR3]\]CanadaModerate and severe COPD exacerbationsAll exacerbations (n = 609)151Moderate exacerbation140Severe exacerbation151Mancini et al. \[[@CR53]\]COPD patientsCoronary revascularization (n = 946)Prior year 2.6--5.9 %Without MI (n = 18,774)Prior year 1.6--7.3 %Gonzalez et al. \[[@CR80]\]\>66 years, received ≥3 respiratory medicationsWomen (n = 19,260)Prior year 2.7 %Men (n = 23,893)Prior year 2.6 %Macie et al. \[[@CR81]\]Manitoba (1997--2000)Drug claim for obstructive airways diseaseAll recipients (n = 6,041)3.2 %Control (n = 60,410)5.2 %Ernst et al. \[[@CR82]\]Hospitalized with PneumoniaCase (n = 23,942)14.5 %Control (n = 95,768)3.6 %Chan et al. \[[@CR20]\]COPD DiagnosisTiotropium (n = 608)8.4 %Placebo (n = 305)8.2 %Gershon et al. \[[@CR42]\]Ontario (2003--2007)≥66 yearsLong-acting anticholinergic (n = 28,563)33.3 %Long-acting beta-agonist (n = 17,840)30.7 %Monfared et al. \[[@CR83]\](1990--1996)Elderly COPD patientsRAMQ database (n = 1233)32.7 %MED-ECHO database (n = 1206)32.0 %Polisena et al. \[[@CR17]\]Calgary (1998--2009)≥60 years (mean age)Telephone support32--46 %Usual Care51--66 %Goodridge et al. \[[@CR52]\](Deceased in 2004)COPD or lung cancer deathAll patients (n = 1098)80.4 %Aaron et al. \[[@CR56]\]Canada (1995--2004)COPD patientsTiotropium + Plac (n = 156)62Tiotropium + Salmeterol (n = 148)48Tiotropium + Fluticasone-Salmeterol (n = 145)41Benayoun et al. \[[@CR84]\](1996--1997)\>45 years, initiating treatment with combination inhalerCombined Bronchodilator (n = 641)Prior year 202Double-users (n = 411)Prior year 279Stephenson et al. \[[@CR40]\]Ontario (2003--2010)\>66 years, Concomitant dementia and COPDChEI users (n = 7166)Prior year 469ChEI non-users (n = 7166)Prior year 403Bourbeau et al. \[[@CR85]\]≥55 years, without asthma initiating COPD treatmentCase (n = 843)Current ICS use 275, past user 141Control (n = 11,030)Current ICS use 2994, past user 1357Beauchesne et al. \[[@CR77]\](1995--2004)COPD patientsHome management (n = 152)100Bourbeau et al. \[[@CR44]\]Advanced COPD, ≥1 hospitalization for exacerbation in last yearUsual care (n = 95)Prior, 152\
Year 1, 118Self-management care (n = 96)Prior year, 158\
Year 1, 71Disano et al. \[[@CR86]\](2003--2006)Ambulatory care COPDLow SES381^a^Average SES210^a^High SES129^a^Keenan et al. \[[@CR87]\]LondonCOPD with exacerbation at emergency roomAll patients (n = 25)355 (over 3 years 2 months)Dormuth et al. \[[@CR60]\]British Columbia≥45 years, 2.5-year period after public coveragePredicted use42,735Observed use44,007*PY* patient years^a^Rates per 100,000 peopleTable 3Summary of physician visit evidenceReferencesGeographic region (study years)PatientsArms or cohortsPhysician visits, \# or  % patients\# of physician visitsMean annual physician visits, \# visits/patientBlais et al. \[[@CR41]\]Quebec (Feb 2003--Jan 2007)≥40 years of ageBudesonide/formoterol (n = 1131)58.5 %19561.73 visitsPropionate/salmeterol (n = 1131)59.7 %17791.57 visitsOhinmaa et al. \[[@CR46]\]AlbertaAdult from Canadian Community Health Survey20--44 years6.52 visits45--64 years5.63 visits\>65 years8.10 visitsGoodridge et al. \[[@CR52]\](Deceased in 2004)COPD or lung cancer deathAll patients (n = 1098)59.8 % (\>24 visits within 12 months of death)28.0 visits (12 months prior to death)Polisena et al. \[[@CR17]\]Calgary (1998--2009)≥60 years of ageTelephone supportPCP; 0.48 vs. 1.18 UC\
Office visits; 5.0 vs. 6.0 UCHome telemonitoringOffice visits; 3.2 vs 2.3 UCRowe et al. \[[@CR34]\]US, Canada≥55 year, stable COPDCanadian patients (n = 63)0 urgent clinic visits, prior-yearUS patients (n = 334)0 urgent clinic visits, prior-yearSin et al. \[[@CR38]\](1992--1997)age ≥65 years, discharged diagnosis of COPDNo-inhaled corticosteroid (n = 11,139)4.1 visits, prior yearInhaled corticosteroid (n = 11,481)4.1 visits, prior yearMancini et al. \[[@CR53]\]COPD patients, with CV revascularization and without MI newly treated with NSAIDSHigh-risk cohort cases (n = 946)20 visits, prior yearHigh-risk controls (n = 18,774)19 visits, prior yearLow-risk cohort cases (n = 4907)5 visits, prior yearLow-risk controls (n = 98,097)5 visits, prior yearBeaulieu et al. \[[@CR48]\]Moderate-severe COPDSelf-administered Rx (n = 46)0.8 visits (prior 6-months)Control (n = 43)0.7 visits (prior 6-months)Johnston et al. \[[@CR32]\]Hamilton, Ontario (Dec 2006--Jan 2007)≥40 year, COPD of mixed severityGOLD stratum 0 (n = 39)9GOLD stratum 1 and 2 (n = 31)15GOLD stratum 3 and 4 (n = 44)15Bourbeau et al. \[[@CR44]\]Advanced COPD, ≥1 hospitalization for exacerbation in last yearUsual Care (n = 95)Scheduled 309\
Unscheduled 112Self-management care (n = 96)Scheduled 354\
Unscheduled 46Sedeno et al. \[[@CR21]\]COPD patientsUsual care (n = 81)30.9 %Self-management group (n = 85)8.2 %Bischoff et al. \[[@CR39]\]COPD patients, ≥40 yearsAll patients (n = 217)Unscheduled Visits; 70Chapman et al. \[[@CR1]\], Wouters et al. \[[@CR37]\]Canada, 7 countries North America and Europe (1 year study)Diagnosed/undiagnosed COPD patientsAll patients (n = 401)Scheduled PCP; 225\
Unscheduled PCP; 175Scheduled 1506\
Unscheduled 175Macie et al. \[[@CR81]\]Manitoba (1997--2000)Drug claim for obstructive airways diseaseAll recipients (n = 6041)0--1 visit; 18.0\
2--3 visits; 23.0 %\
4--9 visits; 36.6 %\
≥10 visits; 22.4 %Control (n = 60,410)0--1 visit; 32.8 %\
2--3 visits; 24.0 %\
4--9 visits; 29.1 %\
≥10 visits; 14.1 %Disano et al. \[[@CR86]\]Canada (fiscal years 2003--04, 2004--05 and 2005--06)Children under 20 years, fiscal years 2003--04, 2004--05 and 2005--06All (46,173)48 %Underweight (BMI \<18.5)42 %Normal weight (BMI 18.5--24.9)56 %Overweight (BMI 25--29.9)55 %Obese (BMI ≥ 30)32 %FitzGerald et al. \[[@CR43]\]Canada (1 year study)≥40 years of agePatients with exacerbations (n = 278)255Stephenson et al. \[[@CR40]\]Ontario (2003--2010)\>66 years, Concomitant dementia and COPDChEI users (n = 7166)1 visit, 36; ≥2 visits 7062ChEI non-users (n = 7166)1 visit, 131; ≥2 visits 6940Dormuth et al. \[[@CR88]\]British Columbia (1997--2004)≥65 years of agePolicy Group (n = 19,985)6-months prior/follow-up\
0--4 visits; 4610\
≥5 visits; 15,375Pre-policy group (n = 17,335)6-months prior/follow-up\
0--4 visits; 4439\
≥5 visits; 12,896Mittmann et al. \[[@CR3]\]CanadaModerate and severe COPD exacerbationsAll exacerbations (n = 609)618Moderate exacerbation574Severe exacerbation44Sin et al. \[[@CR89]\]Alberta (1996--1997)General Population (2.8 million)Aboriginals15,712Non-aboriginals275,134Dormuth et al. \[[@CR60]\]British Columbia≥45 years, 2.5-year period after public coveragePredicted use2,073,233 (over 2.5 years)Observed use2,094,360 (over 2.5 years)Rowe et al. \[[@CR30]\]Alberta (1999--2005)≥55 years at time of ED visitAll Patients (n = 7302)GP 107,405\
Int Med 13,907\
Resp Med 5287Moineddin et al. \[[@CR90]\]Ontario (1992--2002)All patients with at least 1 primary care visit4,662,735 over 11 years*PY* patient years, *PCP* primary care physician, *UC* usual care, *Rx* prescription

### Emergency department (ED) visits {#Sec12}

Emergency department visits were reported as an outcome in 23 out of the 58 studies (Table [1](#Tab1){ref-type="table"}). A number of studies reported the mean number of emergency department visits which ranged from 0.1 to 2.20 per year \[[@CR1], [@CR17], [@CR28]--[@CR39]\]. Eleven studies reported that 7.2--63.2 % of patients with COPD visited the emergency department \[[@CR1], [@CR17], [@CR21], [@CR28], [@CR30], [@CR35], [@CR40]--[@CR44]\]. Johnston \[[@CR32]\] reported the mean annual number of ED visits by disease severity. The instrument used to assess disease severity was developed by the global initiative for chronic obstructive lung disease (GOLD) and categorizes patients from mild to very severe in 4 levels (GOLD 1--4 stratum). The mean number of annual ED visits ranged from 1.4 (GOLD stratum 1 and 2) to 1.8 (GOLD stratum 3 and 4) in COPD patients with an exacerbation \[[@CR32]\].

Three studies reported how different pre/post interventions affected ED visits in COPD patients. Overall ED visits were less in COPD patients with self-management education or self-care management programs; however, integrated care appeared to provide no benefit on the annual mean number of ED visits \[[@CR28], [@CR29], [@CR44]\].

### Hospitalization {#Sec13}

Hospitalization was reported as an outcome in 38 of the 58 studies (Table [2](#Tab2){ref-type="table"}). The rates were reported as either pre- or post- index hospitalizations. The mean number of annual hospital visits per COPD patient per year ranged from: 0--1.5 pre-index to 0--5.19 post-index \[[@CR1], [@CR28], [@CR29], [@CR32], [@CR34], [@CR41], [@CR43], [@CR45]--[@CR48]\]. Three studies reported the rates of hospitalization according to disease severity and/or COPD exacerbations and found higher rates of hospitalization in more severe patients (GOLD stratum 3 or 4) and those with more severe exacerbations \[[@CR3], [@CR32], [@CR43]\]. Hospital readmission rates varied between three studies with Sin \[[@CR49]\] reporting a rate of 25 % for COPD patients ≥65 years of age, Chen \[[@CR50]\] reporting a rate of 49.1 % in patients ≥40 years of age, and Wong \[[@CR47]\] reporting 3.3 mean annual number of hospital readmissions in patients with a diagnosis of AECOPD.

The relationship of COPD hospitalization rates to patient demographic characteristics was examined in three studies. A higher rate of hospitalization was found in male COPD patients \[126.1/1000 patient years (PY)\] than females (74.3/1000 PY) and in those \>65 years of age (5.19 visits/patient annually) versus those 45--64 years of age (3.45 visits/patient annually) \[[@CR46], [@CR51]\]. One study found that COPD patients' body mass index (BMI) status had no effect on hospitalization rates \[[@CR45]\].

Lastly, three studies examined the effects of different interventions on hospitalization rates in COPD patients. Moullec \[[@CR28]\] found that integrated care (a combination of self-management education and case management) resulted in a decreased mean number of hospitalizations compared to usual care. Lebrecque \[[@CR29]\] and Sedeno \[[@CR21]\] found that self-management interventions also reduced hospitalizations compared to usual care.

### Physician visits {#Sec14}

A total of 24 studies reported the rate of physician visits for COPD (Table [3](#Tab3){ref-type="table"}). The annual rate of physician visits post-index for COPD patients ranged between 1.57 and 28 visits annually \[[@CR41], [@CR46], [@CR52]\]. Two studies found that elderly COPD patients (\>65 years) had high rates of physician visits compared to younger patients (from 4.1 to 8.1 visits/year) \[[@CR38], [@CR46]\], one study found those at high risk for CV-related comorbidities had higher physician visit rates compared to those with low risk (20 vs. 5 visits per year) \[[@CR53]\], and one study reported that COPD patients diagnosed with GOLD stratum 1--4 had a higher number of exacerbations requiring a physician visit compared to those with GOLD stratum 0 (15 vs. 9 visits, respectively) \[[@CR32]\]. Goodridge \[[@CR52]\] found the highest rate of physician visits for COPD patients was within 12 months of death (28 visits/year) and Rowe \[[@CR34]\] found that Canadian and US stable COPD patients had similar mean annual urgent clinic visit rates. Lastly, two studies found that self-management interventions reduced the number of unscheduled physician visits \[[@CR21], [@CR44]\] and a review article found a reduction in the number of annual physician visits for patients receiving telephone support \[[@CR17]\].

Humanistic burden evidence {#Sec15}
--------------------------

### Overview {#Sec16}

A total of 12 studies were identified describing the humanistic burden by measuring the effect of COPD on a patient's health-related quality of life (HRQoL) and physical activity (Table [4](#Tab4){ref-type="table"}). Study timeframes were not reported in three studies and variation was found in the definition of COPD across all studies. With regard to the type of HRQoL instruments used, 4 studies \[[@CR22], [@CR25], [@CR54], [@CR55]\] reported outcomes for the 36-item short form health survey (SF-36) and 5 studies reported results for The St. George Respiratory Questionnaire (SGRQ) \[[@CR20], [@CR22], [@CR27], [@CR54], [@CR56]\]. Other scales that were used to assess HRQoL were the chronic respiratory disease (CRD) Index Questionnaire, the sickness impact profile (SIP) and the Chronic Respiratory Questionnaire (CRQ).Table 4Summary of humanistic burden evidenceReferences/study periodPatient groupNScaleBaseline score, mean (SD)Endpoint score, mean (SD)Change from baseline, mean (SD)SF-36 score Appleton et al. \[[@CR54]\]/November 1999--September 2001Salmeterol172PH36.5 (10.0) \[N = 146\]37.1 (10.5) \[N = 131\]0.3 (7.7) \[N = 146\]; mean difference vs placebo: 0.30; 95 % CI (−1.3, 1.9)ME49.3 (10.8) \[N = 146\]50.0 (10.5) \[N = 131\]1.1 (10.0) \[N = 146\]; mean difference vs placebo 0.03; 95 % CI (−1.9, 1.9)Placebo176PH36.1 (9.5) \[N = 156\]36.8 (10.3) \[N = 144\]0.1 (6.4) \[N = 156\]ME48.8 (11.0) \[N = 156\]50.3 (10.6) \[N = 144\]1.1 (9.1) \[N = 156\] HajGhanbari et al. \[[@CR25]\]/study period not reportedCOPD patients47PH35.2 (1.7) p = 0.000; AMD vs control: 16.9ME42.0 (1.8) p = 0.000; AMD vs control: 12.8Healthy controls47PH52.0 (1.3)ME54.7 (1.30) Moullec et al. \[[@CR22]\]/Apr 2004--May 2006Usual care50PH37 (10)ME47 (12)Intervention60PH35 (8) p = 0.33ME45 (12) p = 0.26 Lacasse et al. \[[@CR55]\]/12 weeksParoxetine12PH18.6 (10.0)MH53.1(23.2)Placebo11PH19.0 (9.9); p = 0.9MH58.0 (16.8); p = 0.4SGRQ scores Appleton et al. \[[@CR54]\]/November 1999--September 2001Salmeterol172T46.2 (18.0) \[N = 150\]41.6 (19.0) \[N = 124\]−2.9 (11.1) \[N = 150\]S59.6 (18.4) \[N = 15055.4 (19.7) \[N = 124\]−3.0 (15.8) \[N = 150\]A61.6 (21.9) \[N = 15053.3 (23.8) \[N = 124\]−5.9 (15.4) \[N = 150\]I33.5 (20.7) \[N = 150\]30.6 (20.0) \[N = 124\]−1.2 (13.6) \[N = 150\]Placebo176T46.8 (16.6) \[N = 157\]44.7 (18.6) \[N = 139\]−1.3 (10.3) \[N = 157\]S56.7 (19.6) \[N = 157\]57.3 (21.6) \[N = 139\]1.4 (15.5) \[N = 157\]A62.7 (18.9) \[N = 157\]59.7 (22.4) \[N = 139\]−3.0 (15.0) \[N = 157\]I34.8 (18.9) \[N = 157\]32.4 (20.3) \[N = 139\]−1.2 (11.5) \[N = 157\] Aaron et al. \[[@CR56]\]/October 2003--January 2006Tiotropium + placebo156T−4.5SAITiotropium + salmeterol148T−6.3, p = 0.02SAITiotropium + fluticasone/salmeterol145T−8.6, p = 0.01SAI Chan et al. \[[@CR20]\]/1 yearTiotropium608T40.9S44.4AI28.5Placebo305T43.7, p \< 0.01S49.3, p \< 0.01AI31.3, p \< 0.01 Low et al. \[[@CR27]\]/study period not reportedPatient67T--S57.68 (24.71) \[N = 66\]; mean difference vs spouse: 1.73; p = 0.497A70.42 (17.44) \[N = 67\]; mean difference vs spouse: −0.21; p = 0.771I41.05 (22.83) \[N = 66\]; mean difference vs spouse: 5.6; p = 0.002Spouse67T--S59.41 (23.05) \[N = 65\]A70.21 (18.72) \[N = 66\]I47.29 (23.12) \[N = 65\] Moullec et al. \[[@CR22]\]/Apr 2004--May 2006Usual care50T49 (18)S55 (16)A66 (23)I38 (20)Intervention60T48 (16), p = 0.72S54 (18), p = 0.74A65 (20), p = 0.85I37 (19), p = 0.72Chronic Respiratory Questionnaire Scores (CRQ) Lacasse et al. \[[@CR55]\]/12 weeksParoxetine12TGD3.4 (0.9), p = 1.0E3.5 (0.9), p = 0.8M4.3 (1.0), p = 0.2F3.6 (0.8), p = 0.3Placebo11TG--D3.4 (0.6)E3.7 (1.0)M4.9 (0.9)F3.2 (1.1) Bourbeau et al. \[[@CR57]\] 6 monthsBudesonide39TG--D19.9 (6.2)−1.8 (−3.9 to 0.2)E37.9 (6.9)−1.9 (−5.3 to 1.4)M21.4 (4.2)−0.5 (−2.4 to 1.4)F20.7 (3.6)−3.0 (−4.9 to −1.2)Placebo40TG----D19.5 (5.8)−0.5 (−2.3 to −1.3)E36.2 (9.6)−0.6 (−3.4 to 2.2)M21.7 (5.8)−1.3 (−3.0 to 0.5)F19.3 (5.6)−1.4 (−3.1 to 0.3) Leigh et al. \[[@CR24]\]/4-week treatment periodOverall population40TG17.5 (3.6)Post-PB: 18.1 (3.5)\
Post-BDN: 19.4 (3.4)\
Post-PDN: 21.0 (3.4)D3.7 (1.0)Post-PB: 3.9 (0.9)\
Post-BDN: 4.4 (1.1)\
Post-PDN: 4.6 (1.3)EMFPhysical activity Vozoris et al. \[[@CR23]\]/1994--2007Obese COPD patients858Inactivity^a^; restricted activity^a^Inactive: 68 % patients\
Activity restriction: 72 % patientsNon-obese COPD patients2611Inactivity^a^; restricted activity^a^Inactive: 60 % patients\
Activity restriction: 60 % patients Rocker et al. \[[@CR26]\]. Study period not reportedSevere, stable COPD patients8Palliative performance scaleScores ranged from 50 to 70 %*A* activity score, *AMD* absolute mean difference, *BDN* budesonide, *D* dyspnea, *E* emotional function, *F* fatigue, *M* mastery, *ME* Mental Health summary score, *PB* placebo, *PDN* prednisone, *PH* Physical Health summary score, *S* symptoms score, *T* total score, *TG* total (Global) score, *I* impact score^a^Canadian Fitness and Lifestyle Research Institute defined Inactivity as total daily energy expenditure value of \< 1.5 kcal/kg/day; restricted activity: sometimes or often had difficulty with simple activities such as walking, climbing stairs, and bending

### Sf-36 {#Sec17}

Of the 4 studies reporting SF-36 evidence, one study found that COPD patients receiving salmeterol did not experience significant improvement in their SF-36 mental or physical health summary scores compared to baseline \[[@CR54]\]. In contrast, a case--control study reported an absolute mean difference of 16.9 in the SF-36 physical health summary score and 12.8 in the mental component score for COPD patients compared to healthy controls. The study also indicated a significantly worse (p \< 0.001) level of functioning for patients with COPD \[[@CR25]\].

### St George's Respiratory Questionnaire (SGRQ) {#Sec18}

Four of the five studies reporting SGRQ data compared an intervention to placebo or usual care in a COPD population \[[@CR20], [@CR22], [@CR54], [@CR56]\], while one study reported data for COPD patients versus their spouses \[[@CR27]\]. Three RCTs found pharmaceutical agents (tiotropium, salmeterol, tiotropium plus salmeterol and tiotropium plus fluticasone/salmeterol) significantly improved patients' quality of life as measured by the SGRQ score \[[@CR20], [@CR54], [@CR56]\]. Of the remaining two studies, one cross-sectional survey found a significant mean difference (5.6, p = 0.002) for the SGRQ impact of disease scores between COPD patients and their non-COPD spouse \[[@CR27]\] and a prospective, observational study reported no significant differences in SGRQ scores at baseline between the self-management education program and usual care groups \[[@CR22]\].

### Chronic Respiratory Questionnaire (CRQ) {#Sec19}

Three studies used the CRQ to assess the quality of life of COPD patients utilizing different pharmaceutical interventions (paroxetine, budesonide, prednisone). Of the three studies, paroxetine (CRQ emotional function domain) and inhaled corticosteroids (budesonide) were found to produce significant improvements in patients' quality of life; however, inhaled corticosteroids (even in 'high' doses) did not appear to provide significant HRQoL improvement over that achieved with oral prednisone \[[@CR24], [@CR55], [@CR57]\].

### Miscellanous HRQoL instruments {#Sec20}

Several studies utilized additional HRQoL instruments to assess the quality of life of COPD patients. A study by HajGhanbari \[[@CR25]\] found that pain severity \[measured by the McGill Pain Questionnaire (MPQ) and brief pain inventory scale (BPI)\] showed moderate to strong negative correlations to the physical component score of the SF-36 (−0.45, −0.61, −0.70, respectively; p \< 0.001). In addition, a cross-sectional survey study using the SIP found significant differences in the mean score between patients' and healthy spouses' ratings of the SIP physical score (p = 0.009), but non-significant differences in psychosocial score (p = 0.497) \[[@CR27]\]. Finally, a single RCT conducted by Aaron \[[@CR58]\] using the chronic respiratory disease index HRQoL instrument (CRD) found that prednisone use did not result in a significant (p = 0.14) overall health benefit (total score) when compared to placebo, although prednisone reduced the incidence of relapse and improved both lung function and dyspnea.

### Physical activity {#Sec21}

Three studies reported on physical activity related to the burden of COPD. A cross-sectional study using the Canadian national health survey data (1994--2007) found that approximately 68 % of obese and 60 % of non-obese COPD patients were inactive. Additionally, approximately 72 % of obese and 60 % of non-obese COPD patients reported activity restriction \[[@CR23]\]. Furthermore, a cross-sectional study by Rocker \[[@CR26]\] in patients with severe, stable COPD found that scores on the palliative performance scale from semi-structured interviews ranged from 50 to 70 % and that all patients had a score of 5 on the Medical Research Council dyspnea scale (i.e., they were too short of breath to leave their homes or were breathless when dressing or undressing). The significance of pain in COPD patients was reflected in pain-related interference in activities, which may partly account for the lower SF-36 physical component scores in HRQoL and the lower physical activity scores on the community health activities model program for seniors (CHAMPS) questionnaire \[[@CR25]\].

Economic burden evidence {#Sec22}
------------------------

### Overview {#Sec23}

A total of 5 studies contained outcomes of interest and were included in this review. Of the 5 studies, 4 studies reported the patient level direct costs and 2 studies reported population level direct costs for COPD patients (Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}).Table 5Summary of average annual patient level direct costs evidence (CAN\$)References (study period)CategoriesPatient groupPatient perspective inflated cost/patientSocietal perspective inflated cost/patientChapman et al. \[[@CR1]\] (12 months)AllAll\$2444.17\$3910.39GenderMale\$1941.09\$2817.88Female\$2926.30\$4956.03Smoking statusFormer smokers\$3348.67\$4702.55Current smokers\$1357.06\$2958.41ComorbiditiesYes\$2506.92\$4568.22No\$2370.68\$3127.96Education statusLess educated\$3043.48\$4540.89More educated\$2142.85\$3638.46Wouters et al. \[[@CR37]\] (1 year)AllAll\$2378.59\$6693.37GenderMaleNR\$2741.62FemaleNR\$4254.24Smoking statusFormer smokersNR\$4575.67Current smokersNR\$2877.75Education statusLess educatedNR\$4418.73Well educatedNR\$3539.53Mittmann et al. \[[@CR3]\] (52 weeks)Moderate exacerbationITT population\$718.48NRClinically evaluable population\$847.38NRSevere exacerbationITT population10,712.14NRClinically evaluable population11,156.01NRMaleki-Yazdi et al. \[[@CR59]\] (Oct 2009 and Jan 2010)AllAll\$4391.16NRAcute exacerbationClinically evaluable population\$3214.75NR*ITT* intention to treat, *NR* not reportedTable 6Summary of average annual population level direct costs evidence (CAN\$)References (study period)PopulationResourceInflated 2012 CAN\$Dormuth et al. \[[@CR60]\] (Jul 2007--Dec 2009)Residents of British Columbia, 45+ years oldMedication (inhaled anticholinergic)\$26,298,835.28 (ministry paid: \$13,276,279.45, out of pocket: \$13,022,555.82)Any hospital admission\$310,494,472.10Emergency COPD admission\$59,456,281.50Mittmann et al. \[[@CR3]\] (52 weeks)Mean age of 68.6 yearsModerate exacerbation\$182.7--\$254.44 millionSevere exacerbation\$469.64--\$642.26 million

### Patient level direct costs {#Sec24}

Overall, the average total cost per patient was reported from both a patient perspective and a society perspective (accounting for inflation) and ranged between CAN \$2444.17--CAN \$4391.16 (patient perspective) and CAN \$3910.39--CAN \$6693.37 (societal perspective) annually. The average cost per acute COPD exacerbation reported by Mittmann \[[@CR3]\] and Maleki-Yazdi \[[@CR59]\] ranged from \$718--\$11,156 and the cost was found to increase with the severity of the exacerbation. No studies were found to examine the relationship of cost to overall disease severity.

Two studies examined differences in costs based on patient characteristics. Chapman \[[@CR1]\] and Wouters \[[@CR37]\] both reported female COPD patients incurred more costs compared to male patients from both a patient and a societal perspective (additional \$985/patient from a patient perspective, \$1513--2138/patient from a societal perspective). In addition, these studies also found that former smokers incurred more costs than current smokers (additional \$1992/patient from a patient perspective, \$1698--\$1744/patient from a societal perspective) and that COPD patients with less education incurred more costs than those who are more highly educated (additional \$901/patient from a patient perspective, \$879--902/patient from a societal perspective). Lastly, Chapman \[[@CR1]\] reported that patients with comorbidities were more costly than those without comorbidities (additional \$136/patient from a patient perspective, \$1440/patient from a societal perspective).

### Population level direct costs {#Sec25}

Population level direct costs (in Canadian dollars) were examined in two studies (Table [6](#Tab6){ref-type="table"}). Dormuth \[[@CR60]\] found that residents of British Columbia who were dispensed an inhaled anti-cholinergic (IAC) medication (ipratropium or tiotropium) cost \$26,298,835 annually over 2.5 years for IACs (Ministry of Health \$13,276,279, out of pocket \$13,022,556), \$310,494,472 for any hospital admission and \$59,456,281 for emergency COPD admissions over the 2.5 year period. The second study by Mittmann \[[@CR3]\] estimated that moderate COPD exacerbations cost \$182.70--\$254.44 million annually while severe exacerbations cost \$469.64--\$642.26 million annually in Canada.

Discussion {#Sec26}
==========

COPD is one of the world's most common health problems \[[@CR2]\]. This review found evidence that the clinical, economic and humanistic burden of COPD is substantial in Canada. COPD patients were found to average 0--4 annual emergency department visits, 0.3--1.5 annual hospital visits, and 0.7--5 annual physician visits which are similar to the rates reported worldwide. Variance in these rates across studies may reflect population differences, methodological differences and/or treatment pattern differences between studies. In Canada, the health care services are provided by the private sectors but they are delivered through publicly funded health care systems. For instance, basic services such as physician care are provided by private doctors but the physician fees are paid for by the government. Hospital care is delivered by publicly funded hospitals which are mostly independent institutions incorporated under provincial Corporations Acts. The universal health care system, however, does not include coverage of prescription medication; drug benefit plans for eligible groups are available under provincial and territorial governments.

In terms of ED services, an international survey found that around the world, the percentage of COPD patients using ED services ranges from 1 % (China) to 25 % (Brazil) \[[@CR61]\]. The relatively small number of ED visits found for Canadian COPD patients would suggest that the use of ED services for COPD patients may fall on the lower end worldwide. Hospitalization rates, hospital readmission rates, and the number of physician visits for Canadian COPD patients were found to be consistent with rates found in the US \[[@CR62]--[@CR64]\]. Additionally, trends of increasing healthcare resource use as COPD worsens are consistent with worldwide data \[[@CR61], [@CR65]\].

Primary care has been reported to have the greatest proportion of worldwide burden in the treatment of COPD. Furthermore, increasing severity of COPD imposes a greater burden on the use of primary care resources \[[@CR61]\]. Evidence was found that self-care management programs may help with reducing the number of ED visits, hospitalizations, and physician visits. Additionally, telephone support services were found to reduce the number of physician office visits. Integrated care programs, however, appear to reduce the mean number of hospitalizations but not ED visits.

COPD has a profound impact on patients' quality of life \[[@CR66]\]. Evidence found in this review, while not overwhelming, found that Canadians with COPD have a poorer quality of life. Worldwide data suggests that up to 45 % of COPD patients experience pain and that increases in pain are associated with disease progression \[[@CR67]--[@CR72]\]. The significance of pain in COPD patients was reflected in greater pain-related interference on activities of daily living. In the Canadian Hidden Depths survey, COPD symptoms were found to have a significant effect on a range of daily activities (including climbing stairs, housework, getting dressed and sleeping) for a majority of respondents \[[@CR73]\]. Clinicians face challenges in treating COPD related pain in that opioids, common pharmacotherapy, are not recommended for use in COPD patients, presumably due to their effects on the reduction of breathing rates which may further exacerbate COPD \[[@CR4]\]. Additionally, this review found evidence that 60--72 % of COPD patients are inactive and/or have activity restrictions with obese patients having the highest percentages.

Obesity is one of the leading causes of overall morbidity and mortality \[[@CR74], [@CR75]\]. Thus it is not surprising that health consequences of obesity are seen in the COPD population and coupled with progressively worsening lung function. It is therefore important that more research is performed in order to better understand the impact of interventions on the quality of life and how to maximize patient functioning.

Data from this review found the average total cost per COPD patient ranged between CAN \$2444 from a patient perspective to CAN \$6693 from a societal perspective. Moreover, data suggests that the costs rise as the disease severity increases. The clinical burden review found evidence which indicates that healthcare resource utilization increases with exacerbation severity \[[@CR3], [@CR32]\], increasing age \[[@CR46], [@CR76]\], and comorbid cardiovascular disease \[[@CR53]\]. Thus, clinicians should focus on ensuring proper diagnosis, optimizing appropriate care, and the importance of personalized medicine.

This review, like all reviews, is limited by publication bias with respect to the articles that are available. In addition, the articles in this review were a priori limited to the English language and restricted to those published since 2000 to examine the most recent data as the practice of medicine and related burden may change over time. Spatial restrictions were also applied, limiting studies to Canadian populations. However, in spite of these limitations, this review was systematic in nature and therefore by reviewing all available and relevant data, it provides a better and comprehensive understanding of the literature with respect to clinical, humanistic and economic burden of COPD in the Canadian population.

Conclusions {#Sec27}
===========

COPD is currently the fourth leading cause of death among Canadians. This review found that COPD causes a profound impact on healthcare resources and produces a significant clinical, humanistic and economic burden in Canada. This review found evidence that self-care management programs, telephone support services, and integrated care programs may help limit the overall burden to Canadian patients and society.
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